Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nautilus Biotechnology, Inc. - Common Stock (NQ: NAUT )

1.060 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nautilus Biotechnology, Inc. - Common Stock

< Previous 1 2 3 4 Next >
US Stocks Sink; Deere Shares Fall Despite Earnings Beat
U.S. stocks traded down this morning with the Nasdaq Composite falling more than 101 points on Friday. The Dow traded down 0.23% to 34,396.96 while the NASDAQ fell 0.91% to 13,196.22. The S&P 500 also... 
Via Benzinga
Topics Stocks
Exposures US Equities
Nautilus Biotechnology to Participate in Upcoming August Investor Conferences
From Nautilus Biotechnology Inc.
Via GlobeNewswire
Nautilus Biotechnology Reports Second Quarter 2023 Financial Results
From Nautilus Biotechnology Inc.
Via GlobeNewswire
Nautilus Biotechnology to Announce Second Quarter Financial Results on August 2, 2023
From Nautilus Biotechnology Inc.
Via GlobeNewswire
Recap: Nautilus Biotechnology Q3 Earnings
Nautilus Biotechnology (NASDAQ:NAUT) reported its Q3 earnings results on Tuesday, November 1, 2022 at 06:05 AM. Here's what investors need to know about the announcement. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Avid Bioservices Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) shares climbed 422% to $0.5572 after the company announced acquisition of Spyre Therapeutics and concurrent oversubscribed $210 million private... 
Via Benzinga
Top 5 Health Care Stocks That May Crash This Month
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Nautilus Biotechnology to Participate in Upcoming June Investor Conferences
From Nautilus Biotechnology Inc.
Via GlobeNewswire
Nautilus Biotechnology Reports First Quarter 2023 Financial Results
From Nautilus Biotechnology Inc.
Via GlobeNewswire
Nautilus Biotechnology to Announce First Quarter Financial Results on May 2, 2023
From Nautilus Biotechnology Inc.
Via GlobeNewswire
Nautilus Biotechnology to Participate in B. Riley Securities’ Disruptive Biotech Enabling Technologies – Proteomics, Virtual Conference
From Nautilus Biotechnology Inc.
Via GlobeNewswire
Nautilus Biotechnology Announces “First Access Challenge” Winners
Researchers from Buck Institute for Research on Aging, Brigham Young University and University of Southern California awarded early access to Nautilus’ single-molecule protein analysis platform 
From Nautilus Biotechnology Inc.
Via GlobeNewswire
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2022 Financial Results
From Nautilus Biotechnology Inc.
Via GlobeNewswire
Earnings Scheduled For February 23, 2023
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter. 
Via Benzinga
Nautilus Biotechnology to Participate in the 43rd Annual Cowen Health Care Conference
From Nautilus Biotechnology Inc.
Via GlobeNewswire
Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
From Nautilus Biotechnology Inc.
Via GlobeNewswire
Nautilus Biotechnology Expands to San Diego
Proteomics company opens new office in Southern California to facilitate ongoing research and team growth aimed at unlocking the potential of the proteome 
From Nautilus Biotechnology Inc.
Via GlobeNewswire
Nautilus Biotechnology Partners with the Translational Genomics Research Institute (TGen) to Investigate Applications of Single-Molecule Proteomic Analysis in Diffuse Intrinsic Pontine Glioma (DIPG)
Collaboration enables TGen to gain access to data generated on prototype versions of Nautilus’ next-generation proteome analysis platform to advance the study of a rare childhood cancer 
From Nautilus Biotechnology Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 49 companies hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  During Thursday's trading, 138 companies set new 52-week lows. 
Via Benzinga
Nautilus Biotechnology Launches “First Access Challenge”
Open competition allows researchers to be among the first to access potentially groundbreaking proteomic data through the testing of twelve samples on Nautilus’ single-molecule protein analysis... 
From Nautilus Biotechnology Inc.
Via GlobeNewswire
Nautilus Biotechnology Reports Third Quarter 2022 Financial Results
From Nautilus Biotechnology Inc.
Via GlobeNewswire
Nautilus Biotechnology to Announce Third Quarter 2022 Financial Results on November 1, 2022
From Nautilus Biotechnology Inc.
Via GlobeNewswire
$7.3 Million Bet On This Penny Stock? Check Out These 4 Penny Stocks Insiders Are Buying
The Dow Jones dropped more than 600 points on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
  
Via Benzinga
Earnings Scheduled For November 1, 2022
Companies Reporting Before The Bell • BP (NYSE:BP) is estimated to report quarterly earnings at $2.07 per share on revenue of $64.76 billion. 
Via Benzinga
Why GigaCloud Technology Jumped 206%; Here Are 79 Biggest Movers From Yesterday
Gainers GigaCloud Technology Inc (NASDAQ: GCT) shares jumped 206% to close at $48.01 on Friday on continued volatility following the company's IPO on Thursday. 
Via Benzinga
$1.2 Million Bet On Gannett? Check Out These 3 Penny Stocks Insiders Are Buying
U.S. stock futures traded slightly higher this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or... 
Via Benzinga
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.